5
Dec
2022
Tag: drug pricing
27
Apr
2020
Bionest
Actions Around Drug Pricing Centering on Insulin
An increasing number of diabetes patients face affordability challenges for their insulin. How are pharma companies and the government responding?
2
Dec
2019
Bionest
The Relationship Between ICER and Industry is Evolving
ICER is expected to update the assessment framework underpinning its evidence reports on new drugs and health care interventions at the end of this year. What changes are likely to be made?
18
Feb
2019
Bionest
One-and-Done Pricing Challenges
As more gene and cell therapies come to market, a big challenge facing both drug developers and payers is designing and instituting appropriate pricing models for these one-time, potentially curative treatments. Innovation should be rewarded, and a curative — or at least, very long-lasting — treatment is likely to save significant dollars in the typical...
12
Feb
2019
Bionest
Drug Pricing: A Key Political Issue for 2019?
Drug pricing is clearly going to be one of the major topics of discussion — and a key political issue — in 2019. Drug makers began the New Year with price increases in the United States on more than 250 prescription drugs. In response, House Democrats, led by the Chairman of the House Oversight Committee,...
2
Jan
2019
Bionest
Happy New Year — Some Thoughts on the Year to Come
Welcome to 2019. We hope you enjoyed the holidays and look forward to meeting and greeting many of you next week in San Francisco for Biotech Week. Several members of the Bionest team will be in attendance, and if you’d like to get together, we look forward to hearing from you. Last year, we...
14
Nov
2018
Bionest
A Crowded Field for Migraine Therapies, Where Recently There Were None
Back in March, when we first wrote about migraine drug development, there were no approved therapies addressing the underlying mechanisms of these painful, sometimes chronic, headaches — the most prevalent neurological disorder worldwide. Now, three such drugs have reached the market. The three drugs — Aimovig (erenumab) from Amgen/Novartis, Ajovy (fremanezumab) from Teva Pharmaceuticals,...
29
Oct
2018
Bionest
First RNAi Drug Hits the Market — At a Very High Price
On August 13, the U.S. Food and Drug Administration (FDA) approved Alnylam’s Onpattro (patisiran), rapidly followed by that product’s approval in Europe three weeks later. Onpattro, which we previously wrote about, is the first RNAi-based treatment to reach the marketplace. It is intended to treat peripheral nerve disease caused by a rare genetic condition called...
1
Oct
2018
Bionest
The Growing Influence of ICER
We have previously written about the Institute for Clinical and Economic Review (ICER), the independent watchdog whose mission is to offer an objective evaluation of the clinical and economic value of prescription drugs, medical tests, and other healthcare innovations. Many European nations have governmental or quasi-governmental agencies, like the United Kingdom’s NICE (the National...
24
Sep
2018